Vanguard Group Inc. Has $302.72 Million Holdings in Amedisys, Inc. (NASDAQ:AMED)

Vanguard Group Inc. grew its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 0.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,241,160 shares of the health services provider's stock after acquiring an additional 12,137 shares during the quarter. Vanguard Group Inc. owned about 9.93% of Amedisys worth $302,724,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of AMED. Pinebridge Investments L.P. acquired a new stake in Amedisys during the 2nd quarter worth approximately $26,000. Neo Ivy Capital Management acquired a new stake in Amedisys during the 2nd quarter worth approximately $44,000. Covestor Ltd increased its position in Amedisys by 88.9% during the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider's stock worth $56,000 after purchasing an additional 152 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Amedisys during the 1st quarter worth approximately $67,000. Finally, Lazard Asset Management LLC acquired a new stake in Amedisys during the 1st quarter worth approximately $68,000. Institutional investors and hedge funds own 94.36% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on AMED shares. StockNews.com started coverage on Amedisys in a report on Saturday, March 23rd. They issued a "buy" rating for the company. Raymond James restated a "market perform" rating on shares of Amedisys in a report on Tuesday. Finally, Royal Bank of Canada upped their price target on Amedisys from $97.00 to $100.00 and gave the stock an "outperform" rating in a report on Monday. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $97.50.

Amedisys Stock Performance

NASDAQ AMED traded down $0.30 during trading hours on Thursday, hitting $92.16. The company had a trading volume of 323,817 shares, compared to its average volume of 299,820. Amedisys, Inc. has a fifty-two week low of $71.19 and a fifty-two week high of $96.44. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $93.56 and a 200-day simple moving average of $93.59. The firm has a market cap of $3.01 billion, a P/E ratio of -297.28, a price-to-earnings-growth ratio of 4.34 and a beta of 0.86.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.10). The company had revenue of $570.79 million during the quarter, compared to analyst estimates of $566.85 million. Amedisys had a positive return on equity of 12.76% and a negative net margin of 0.44%. Amedisys's quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.16 earnings per share. Equities analysts predict that Amedisys, Inc. will post 4.54 EPS for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.